RealD Spark, LLC v. Microsoft Corporation

District Court, W.D. Washington·Decided September 30, 2025·No. 2:22-cv-00942·Unknown

Opinion

UNITED STATES DISTRICT COURT WESTERN DISTRICT OF WASHINGTON REALD SPARK, LLC, CASE NO. 2:22-cv-00942-TL Plaintiff, ORDER ON MOTION TO DISMISS v. COUNTERCLAIMS MICROSOFT CORPORATION, Defendant.

This matter is before the Court on Plaintiff RealD Spark, LLC (“RealD”)’s motion to dismiss Defendant Microsoft Corporation’s counterclaims. Dkt. No. 152. Having reviewed the motion, Microsoft’s response (Dkt. No. 155), RealD’s reply (Dkt. No. 157), and the relevant record, the Court GRANTS the motion. I. BACKGROUND1 This is an intellectual-property case that arises out of disputed technology developed to ward off so-called “Zoom fatigue,” an affliction caused by the physical and psychological strain 1 This background recites only an abbreviated version of the procedural history of this case and specifically focuses on those facts and procedural developments relevant to the instant motion to dismiss. experienced by videoconference participants. In this case, Plaintiff RealD originally brought four claims against Defendant Microsoft: (1) breach of contract; (2) violation of the Defend Trade Secrets Act, 18 U.S.C. §§ 1836 et seq.; (3) violation of the Washington Uniform Trade Secrets Act, Chapter 19.108 RCW; and (4) patent infringement. See Dkt. No. 1 (complaint).2 RealD

alleged that it had developed an innovative technology, which it called “SocialEyes,” that artificially adjusts the perceived gaze—i.e., the direction in which (or object at which) an individual appears to be looking—of videoconference participants, so that it appears that participants are looking directly at one another other, and not at the cameras or screens on their respective devices. Id. ¶ 14. The technology allows participants to perceive that they are maintaining eye contact with their interlocutors. Id. ¶ 19. RealD asserts that by mimicking eye contact, SocialEyes “makes the video conference more vivid, engaging, and personal for all parties concerned.” Id. RealD’s claim for patent infringement centered around United States Patent No. 10,740,985 (the “’985 Patent”). Id. ¶¶ 75–109. The “’985 Patent describes, among other

things, a method and apparatus for adjusting a digital representation of a head region, particularly by adjusting target features, such as correcting a perceived gaze direction of eyes or modifying the texture and/or shape of features such as the nose, mouth, chin or neck.” Id. ¶ 79. In short, the ’985 Patent represents the foundational technology for SocialEyes. The ’985 Patent covers the technology that makes SocialEyes possible. RealD’s complaint alleges that, after it had collaborated with Microsoft between 2016 and 2019, with an eye toward Microsoft’s licensing or acquiring RealD’s SocialEyes technology, Microsoft abruptly ceased discussions with RealD. Id. ¶¶ 21, 23. Microsoft then hired several

2 As discussed below, RealD voluntarily dismissed the patent-infringement claim. RealD employees who had worked on SocialEyes (id. ¶ 24) and subsequently developed “Eye Contact,” a product similar to SocialEyes (id. ¶ 1). The Eye Contact product, RealD alleged, constituted the “unauthorized and unlicensed use of patented and/or proprietary RealD technology.” Id. Allegedly, products “with the Eye Contact feature infringe[d] . . . the ’985

Patent.” Id. ¶ 88. On December 9, 2022, Microsoft answered RealD’s complaint. Dkt. No. 30. In its answer, Microsoft brought two counterclaims against RealD: (1) declaratory judgment of noninfringement of the ’985 Patent (id. at 48 ¶¶ 7–11); and (2) declaratory judgment of invalidity of the ’985 Patent (id. at 48 ¶¶ 12–16). On October 31, 2023, Microsoft filed an amended answer to RealD’s complaint. Dkt. No. 109. In its amended answer, Microsoft added a third counterclaim: (3) declaratory judgment of invalidity and/or unenforceability of the ’985 Patent for improper inventorship (id. at 49 ¶¶ 17–30). In its first counterclaim, Microsoft seeks a declaration that it has not infringed the ’985 Patent. Id. at 48 ¶ 8. In its second counterclaim, Microsoft seeks a declaration that the ’985 Patent is invalid, because “each claim of the ’985

Patent asserted against Microsoft is invalid for failing to comply with one or more of the requirements for patentability set forth in 35 U.S.C. § 101 et seq., including but not limited to sections 102, 103, and 112.” Id. at 49 ¶ 13. And in its third counterclaim, Microsoft seeks a declaration that RealD’s claims in the ’985 Patent are invalid and unenforceable, because in applying for and obtaining the patent, RealD “fail[ed] to name the actual inventors of the claimed subject matter.” Id. at 50 ¶ 18. Microsoft alleges that the SocialEyes technology, as patented in the ’985 Patent, was developed not at RealD, but rather at the Skolkovo Institute of Science and Technology (“Skoltech”). Id. at 50 ¶ 19. Microsoft alleges that Skoltech inventors “worked in collaboration with the named inventors of the ’985 Patent . . . on eye gaze correction technology”

and “contributed to the inventions in the ’985 Patent.” Id. at 50 ¶¶ 22–23. These Skoltech inventors, however, were not identified as inventors on the ’985 Patent, allegedly rendering the patent “invalid and unenforceable for improper inventorship.” Id. at 51 ¶ 29. On January 11, 2024, RealD moved to voluntarily dismiss its claims of infringement of the ’985 Patent without prejudice, leaving only the breach-of-contract and federal and state trade-

secrets claims as live causes of action. Dkt. No. 125. On January 30, 2024, the Court granted RealD’s motion and dismissed the ’985 Patent claim from this case. Dkt. No. 136. Soon thereafter, on February 8, 2024, RealD issued to Microsoft a covenant not to sue (“the Covenant”) for infringement of the ’985 Patent (Dkt. No. 149-1). Pursuant to the Covenant, RealD unconditionally and irrevocably covenants to refrain, at any time, from directly or indirectly causing the commencement, maintenance, or prosecution of any Action against Microsoft, any of its Affiliates, or their past or present directors, officers, employees, successors, assigns, Customers, manufacturers, distributors, licensees, or other transferees for direct or indirect infringement as to any claim of the ’985 Patent based upon Microsoft making, having made, using, manufacturing, developing, designing, marketing, licensing, distributing, importing, offering for sale, or selling of any service, product, software, or other technology, as they exist today or have existed in the past, including Eye Contact and the currently known extensions or improvements Stare and Teleprompter.

Dkt. No. 149-1 at 1.

Finally, in one further development with respect to the ’985 Patent, on November 19, 2024, in an administrative inter partes review (“IPR”)3 of the ’985 Patent initiated by Microsoft, the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board determined that 18 out of the 19 claims of the ’985 Patent were unpatentable. See Dkt. No. 142-1 (IPR final written decision) at 55.

Free access — add to your briefcase to read the full text and ask questions with AI

RealD Spark, LLC v. Microsoft Corporation, (W.D. Wash. 2025).

RealD Spark, LLC v. Microsoft Corporation (RealD Spark, LLC v. Microsoft Corporation) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Maryland Casualty Co. v. Pacific Coal & Oil Co.
312 U.S. 270 (Supreme Court, 1941)
MedImmune, Inc. v. Genentech, Inc.
549 U.S. 118 (Supreme Court, 2007)
Dow Jones & Co., Inc. v. Ablaise Ltd.
606 F.3d 1338 (Federal Circuit, 2010)
Hewlett-Packard Co. v. ACCELERON LLC
587 F.3d 1358 (Federal Circuit, 2009)
Revolution Eyewear, Inc. v. Aspex Eyewear, Inc.
556 F.3d 1294 (Federal Circuit, 2009)
Prasco, LLC v. Medicis Pharmaceutical Corp.
537 F.3d 1329 (Federal Circuit, 2008)
Cat Tech LLC v. TubeMaster, Inc.
528 F.3d 871 (Federal Circuit, 2008)
Monsanto Co. v. Bayer Bioscience N.V.
514 F.3d 1229 (Federal Circuit, 2008)
Benitec Australia, Ltd. v. Nucleonics, Inc.
495 F.3d 1340 (Federal Circuit, 2007)
SanDisk Corp. v. STMicroelectronics, Inc.
480 F.3d 1372 (Federal Circuit, 2007)
Therasense, Inc. v. Becton, Dickinson and Co.
649 F.3d 1276 (Federal Circuit, 2011)
Streck, Inc. v. Research & Diagnostic Systems, Inc.
665 F.3d 1269 (Federal Circuit, 2012)
Organic Seed Growers and Trade v. Monsanto Company
718 F.3d 1350 (Federal Circuit, 2013)
Harris Corp. v. Federal Express Corp.
670 F. Supp. 2d 1306 (M.D. Florida, 2009)
Cuozzo Speed Technologies, LLC v. Lee
579 U.S. 261 (Supreme Court, 2016)